Pexastimogene Devacirepvec (Pexa Vec)

Phase 2Biologic

Pexastimogene Devacirepvec (Pexa Vec) is one of 49 biologic programs targeting Renal Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal Cell CarcinomaActive, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

77 competitors in Renal Cell Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

24 2

Yervoy

Bristol-Myers Squibb

Phase 3

20 3

Lenvima

Eisai

Phase 3

17 4

Eloxatin

Istodax

Neoral

Inlyta

PPrism Pharmaceuticals

Phase 3

24 8

Adrucil

Farydak

Welireg

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone

Completed·SSillaJen, Inc.·Phase 3·NCT02562755·459 enrolled

A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

Terminated·TTransgene·Phase 1/2·NCT03071094·14 enrolled

Renal Cell Carcinoma1 trial

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Active, not recruiting·SSillaJen, Inc.·Phase 1/2·NCT03294083·89 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Pexastimogene Devacirepvec (Pexa Vec). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pexastimogene Devacirepvec (Pexa Vec) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pexastimogene Devacirepvec (Pexa Vec). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SillaJen, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SSillaJen, Inc.

Pexastimogene Devacirepvec (Pexa Vec)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Renal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News